Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049665 (Melredableukin alfa) in Active Ulcerative Colitis
NCT03943550Phase 1Terminated
- Sponsor
- Roche
- Start
- May 2019
- Primary completion
- Jul 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing RO7049665 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 99. Started May 2019; status: terminated.
02
Drugs
melredableukin alfa
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03943550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943550.